Bruce Hironaka, IgGenix CEO

IgGenix emerges from stealth with $10 mil­lion Se­ries A hop­ing to re-en­gi­neer al­ler­gic cas­cade

A lit­tle over six months af­ter the FDA ap­proved the first treat­ment for peanut al­ler­gies, a new biotech has emerged hop­ing to break through in a field that’s seen vir­tu­al­ly no in­no­va­tion.

IgGenix came out of stealth mode Tues­day morn­ing, an­nounc­ing a $10 mil­lion Se­ries A round to get the com­pa­ny start­ed. The Cal­i­for­nia-based biotech aims to fo­cus not just on peanuts, but all types of food al­ler­gies and re­lat­ed se­ri­ous con­di­tions by de­vel­op­ing a plat­form that can in­ter­fere with the al­ler­gic cas­cade. Fi­nanc­ing was led by Khosla Ven­tures and joined by Park­er Ven­tures.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.